Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Positive allosteric modulation of AMPA receptors via PF4778574 leads to reduced demyelination and clinical disability in experimental models of multiple sclerosis

M. Sindi, M. Dietrich, D. Klees, J. Gruchot, C. Hecker, J. Silbereis, A. Issberner, HP. Hartung, T. Ruck, H. Stark, T. Kurz, P. Küry, SG. Meuth, P. Albrecht

. 2025 ; 16 (-) : 1532877. [pub] 20250305

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25009554

INTRODUCTION: Multiple Sclerosis (MS), a debilitating central nervous system (CNS) disorder, is characterized by inflammation, demyelination, and neuronal degeneration. Despite advancements in immunomodulatory treatments, neuroprotective or restorative strategies remain inadequate. Our research is focusing on the potential of the positive allosteric modulator of AMPA receptors (AMPA-PAM), PF4778574, in addressing MS symptoms. METHODS: We utilized the MOG35-55 induced experimental autoimmune encephalomyelitis (EAE) model in C57BL6J mice to examine PF4778574's therapeutic and prophylactic efficacy. Our comprehensive approach included clinical scoring, optical coherence tomography (OCT), optomotor response (OMR) and histological assessments. Additionally, we explored the effects of PF4778574 in comparison and in combination with the immunomodulatory agent fingolimod, and investigated the impact on Cuprizone induced toxic demyelination. RESULTS: Prophylactic administration of PF4778574 showed notable improvement in clinical EAE indices and reduction in neuronal loss. While it did not diminish microglial activity, it reduced demyelinated areas in optic nerves and in the corpus callosum. Both PF4778574 and fingolimod significantly enhanced clinical EAE scores and decreased demyelination. However, their combination did not yield additional benefits. In the cuprizone model, PF4778574 increased oligodendrocyte precursor and mature myelin-forming cells, suggesting a pro-remyelinating effect. DISCUSSION: PF4778574 demonstrates promise in mitigating EAE effects, especially in terms of clinical disability and demyelination. These results suggest AMPA-PAMs as potential targets of interest for MS treatment beyond immunomodulatory approaches.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009554
003      
CZ-PrNML
005      
20250429135253.0
007      
ta
008      
250415e20250305sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2025.1532877 $2 doi
035    __
$a (PubMed)40109348
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Sindi, Mustafa $u Medical Faculty and University Hospital Düsseldorf, Department of Neurology, Heinrich Heine University, Düsseldorf, Germany
245    10
$a Positive allosteric modulation of AMPA receptors via PF4778574 leads to reduced demyelination and clinical disability in experimental models of multiple sclerosis / $c M. Sindi, M. Dietrich, D. Klees, J. Gruchot, C. Hecker, J. Silbereis, A. Issberner, HP. Hartung, T. Ruck, H. Stark, T. Kurz, P. Küry, SG. Meuth, P. Albrecht
520    9_
$a INTRODUCTION: Multiple Sclerosis (MS), a debilitating central nervous system (CNS) disorder, is characterized by inflammation, demyelination, and neuronal degeneration. Despite advancements in immunomodulatory treatments, neuroprotective or restorative strategies remain inadequate. Our research is focusing on the potential of the positive allosteric modulator of AMPA receptors (AMPA-PAM), PF4778574, in addressing MS symptoms. METHODS: We utilized the MOG35-55 induced experimental autoimmune encephalomyelitis (EAE) model in C57BL6J mice to examine PF4778574's therapeutic and prophylactic efficacy. Our comprehensive approach included clinical scoring, optical coherence tomography (OCT), optomotor response (OMR) and histological assessments. Additionally, we explored the effects of PF4778574 in comparison and in combination with the immunomodulatory agent fingolimod, and investigated the impact on Cuprizone induced toxic demyelination. RESULTS: Prophylactic administration of PF4778574 showed notable improvement in clinical EAE indices and reduction in neuronal loss. While it did not diminish microglial activity, it reduced demyelinated areas in optic nerves and in the corpus callosum. Both PF4778574 and fingolimod significantly enhanced clinical EAE scores and decreased demyelination. However, their combination did not yield additional benefits. In the cuprizone model, PF4778574 increased oligodendrocyte precursor and mature myelin-forming cells, suggesting a pro-remyelinating effect. DISCUSSION: PF4778574 demonstrates promise in mitigating EAE effects, especially in terms of clinical disability and demyelination. These results suggest AMPA-PAMs as potential targets of interest for MS treatment beyond immunomodulatory approaches.
650    _2
$a zvířata $7 D000818
650    _2
$a myši $7 D051379
650    12
$a encefalomyelitida autoimunitní experimentální $x farmakoterapie $x metabolismus $x imunologie $7 D004681
650    12
$a roztroušená skleróza $x farmakoterapie $x metabolismus $x imunologie $7 D009103
650    12
$a AMPA receptory $x metabolismus $7 D018091
650    12
$a myši inbrední C57BL $7 D008810
650    _2
$a alosterická regulace $7 D000494
650    _2
$a demyelinizační nemoci $x farmakoterapie $x metabolismus $7 D003711
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fingolimod hydrochlorid $x farmakologie $x terapeutické užití $7 D000068876
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dietrich, Michael $u Medical Faculty and University Hospital Düsseldorf, Department of Neurology, Heinrich Heine University, Düsseldorf, Germany
700    1_
$a Klees, Diana $u Medical Faculty and University Hospital Düsseldorf, Department of Neurology, Heinrich Heine University, Düsseldorf, Germany
700    1_
$a Gruchot, Joel $u Medical Faculty and University Hospital Düsseldorf, Department of Neurology, Heinrich Heine University, Düsseldorf, Germany
700    1_
$a Hecker, Christina $u Medical Faculty and University Hospital Düsseldorf, Department of Neurology, Heinrich Heine University, Düsseldorf, Germany
700    1_
$a Silbereis, John $u Department of Medical Research, Multiple Sclerosis Unit, Biogen, Cambridge, MA, United States
700    1_
$a Issberner, Andrea $u Medical Faculty and University Hospital Düsseldorf, Department of Neurology, Heinrich Heine University, Düsseldorf, Germany
700    1_
$a Hartung, Hans-Peter $u Medical Faculty and University Hospital Düsseldorf, Department of Neurology, Heinrich Heine University, Düsseldorf, Germany $u Brain and Mind Center, University of Sydney, Sydney, NSW, Australia $u Department of Neurology, Palacky University Olomouc, Olomouc, Czechia
700    1_
$a Ruck, Tobias $u Medical Faculty and University Hospital Düsseldorf, Department of Neurology, Heinrich Heine University, Düsseldorf, Germany
700    1_
$a Stark, Holger $u Faculty of Mathematics and Natural Sciences, Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University, Düsseldorf, Germany
700    1_
$a Kurz, Thomas $u Faculty of Mathematics and Natural Sciences, Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University, Düsseldorf, Germany
700    1_
$a Küry, Patrick $u Medical Faculty and University Hospital Düsseldorf, Department of Neurology, Heinrich Heine University, Düsseldorf, Germany
700    1_
$a Meuth, Sven G $u Medical Faculty and University Hospital Düsseldorf, Department of Neurology, Heinrich Heine University, Düsseldorf, Germany
700    1_
$a Albrecht, Philipp $u Medical Faculty and University Hospital Düsseldorf, Department of Neurology, Heinrich Heine University, Düsseldorf, Germany $u Department of Neurology, Maria Hilf Clinics, Mönchengladbach, Germany
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 16 (20250305), s. 1532877
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40109348 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135248 $b ABA008
999    __
$a ok $b bmc $g 2311127 $s 1246635
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 16 $c - $d 1532877 $e 20250305 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
LZP    __
$a Pubmed-20250415

Find record

Citation metrics

Archiving options